Angle PLC LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
November 28 2018 - 2:01AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
28 November 2018
For immediate release 28 November 2018
ANGLE plc ("the Company")
LEADING US HEMATOPATHOLOGIST APPOINTED AS SCIENTIFIC ADVISOR TO
ANGLE
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce the appointment of Dr Joseph D
Khoury as a Scientific Advisor to the Company's established
Scientific Advisory Board.
Dr Khoury is a recognised expert in diagnostic pathology and has
significant experience in the cytological and morphological
analysis of cancer cells. His expertise is therefore highly
relevant to ANGLE's continuing development of its Parsortix(TM)
system as the liquid biopsy platform of choice for harvesting and
analysing circulating tumour cells and other rare cells from blood
as a means of diagnosing and monitoring disease. Dr Khoury is a
tenured Professor of Pathology and Laboratory Medicine at The
University of Texas MD Anderson Cancer Center in Houston, Texas and
is the Executive Director of the MD Anderson Cancer Network for the
Division of Pathology and Laboratory Medicine and the Director of
the MD Anderson Institutional Immunohistochemistry Laboratory.
Dr Khoury is a leader in translational research focused on
hematolymphoid neoplasia (a class of tumours that affect the blood,
bone marrow, and organs of the immune system). He has authored over
150 publications and has trained numerous clinical and research
fellows. He is an active member of the College of American
Pathologists and has lectured extensively at various institutions
and conferences globally.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Our Parsortix system has been shown to enable the efficient
harvesting of circulating cancer cells and other rare cells in
patient blood. Dr Khoury's expertise in interpreting these cells
and their relevance to a patient's condition, and potentially their
prognosis and treatment, is expected to open up new possibilities
for the use of Parsortix system. We are delighted that we will be
able to benefit from his extensive expertise in this area."
Dr Joseph D Khoury, Executive Director, MD Anderson Cancer
Network, Division of Pathology/Lab Medicine, The University of
Texas MD Anderson Cancer Center, Houston, Texas, said:
"ANGLE's innovative Parsortix platform is at the forefront of
the liquid biopsy market and has the potential to become the market
leader in the next generation of rare cell analysis. I am excited
about our ongoing partnership and look forward to working with
ANGLE to accelerate and expand the clinical applications of this
breakthrough platform to support improved detection and
surveillance techniques for patients with a variety of
diseases."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark in
Europe for the indicated use and FDA clearance is in process for
the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called the Ziplex(R) platform and is based on a
patented flow through array technology. It provides for low cost,
highly multiplexed, rapid and sensitive capture of targets from a
wide variety of sample types. A proprietary chemistry approach
allows for the capture and amplification of over 100 biomarkers
simultaneously in a single reaction. The Ziplex system is ideal for
measuring gene expression and other markers directly from Parsortix
harvests.
ANGLE's proprietary technologies can be combined to provide
automated, sample to answer results in both centralised laboratory
and point -of-use cartridge formats.
Furthermore, ANGLE has established formal collaborations with
world-class cancer centres. These Key Opinion Leaders are working
to identify applications with medical utility (clear benefit to
patients), and to secure clinical data that demonstrates that
utility in patient studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGGPGGUPRUBM
(END) Dow Jones Newswires
November 28, 2018 02:01 ET (07:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
